Contract Win

Fulcrum Pharma PLC
11 October 2007




                               FULCRUM PHARMA PLC
                         ('the Group' or 'the Company')


Fulcrum wins contract to execute a phase III clinical oncology project in Japan

Fulcrum Pharma plc (AIM: FUL), the drug development and regulatory services
company is pleased to announce that its Japanese subsidiary has won a contract
to execute a phase III clinical oncology development study in Japan on behalf of
a major Pharma company. The project runs from September 2007 for four years and
is worth over 600 million JPY (over £2.5 million) in fees.  In conjunction with
other contracts already secured, this contract will mean that at current
capacity, Fulcrum's Japanese subsidiary has a virtually full order book for the
next two years.

Fulcrum has established itself in Japan as a specialist oncology clinical
research organization where it now conducts studies for a range of Japanese
companies, global pharma and Japanese government funded academic groups.

Alastair Devlin, Director of Japanese Strategy of Fulcrum Pharma, said: 'We are
delighted to win this contract with a major Pharma company which has recognised
our strength in oncology. Cancer is the leading cause of death in Japan which is
the world's largest oncology market.'

For further information, please contact:

Fulcrum Pharma PLC
Jon Court, Chief Executive                     Tel: [phone]

Seymour Pierce
Jonathan Wright                                Tel: [phone]

About Fulcrum Pharma plc

Fulcrum Pharma plc is a drug development and regulatory services business that
provides global expertise to achieve drug development and regulatory approval
milestones.

Fulcrum Pharma offers immediate access to a highly credible, integrated
development team that provides strategic and operational leadership required to
ensure that new drugs move smoothly from discovery research to product approval

Fulcrum Pharma is listed on the AIM Market of the London Stock Exchange



                      This information is provided by RNS
            The company news service from the London Stock Exchange